| Identification | Back Directory | [Name]
1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-4-[[6-[4-[4-(6,7,10-trimethoxy-4-oxo-4H-naphtho[1,2-b]pyran-2-yl)phenyl]-1H-1,2,3-triazol-1-yl]hexyl]oxy]- | [CAS]
2411389-67-6 | [Synonyms]
1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-4-[[6-[4-[4-(6,7,10-trimethoxy-4-oxo-4H-naphtho[1,2-b]pyran-2-yl)phenyl]-1H-1,2,3-triazol-1-yl]hexyl]oxy]- | [Molecular Formula]
C43H39N5O10 | [MOL File]
2411389-67-6.mol | [Molecular Weight]
785.8 |
| Hazard Information | Back Directory | [Uses]
PROTAC CYP1B1 degrader-1 (Compound 6C), a α-naphthoflavone chimera derivative, is able to eliminate cytochrome P450 (CYP)1B1-mediated agent resistance via targeted CYP1B1 degradation, with IC50s of 95.1 and 9838.6 nM for CYP1B1 and CYP1A2, respectively. PROTAC CYP1B1 degrader-1 can be used for the research of CYP1B1-overexpressing prostate cancer[1]. | [References]
[1] Li Zhou, et al. Design and synthesis of α-naphthoflavone chimera derivatives able to eliminate cytochrome P450 (CYP)1B1-mediated drug resistance via targeted CYP1B1 degradation. Eur J Med Chem. 2020 Mar 1;189:112028. DOI:10.1016/j.ejmech.2019.112028 |
|
|